Diabetes

Around 50% of patients with Type 2 diabetes have fatty pancreas disease, a substantial yet arguably overlooked metabolic burden.

Researchers reveal the anatomical sites where people with Type 2 diabetes experience a particularly higher risk of fracture.

Londoners are tuning to unsafe alternatives as NHS rollout of weight loss drugs stalls, according to a new report from the London Assembly Health Committee.

Patients with brain metastases and Type 2 diabetes taking GLP-1RAs had a significantly lower risk of mortality over 3 years compared with nonusers in a 2026 cohort study.

GLP-1RAs produce greater weight loss results among women than men, a 2026 systematic review and meta-analysis has found.

The FDA has issued warning letters to 30 telehealth companies for reportedly making false claims about GLP-1 products, amid a major crackdown on pharmaceutical advertisements.

Nicotine-seeking behaviours and activity in the brain’s reward pathway have been found to be dampened through the activation of glucose-like peptide-1 receptors.

A new non-peptide GLP-1 pill proved more effective for weight loss than oral semaglutide in a recent Phase III trial.